These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18948383)

  • 1. Structural insights on physiological functions and pathological effects of alpha-synuclein.
    Bisaglia M; Mammi S; Bubacco L
    FASEB J; 2009 Feb; 23(2):329-40. PubMed ID: 18948383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
    Uversky VN
    J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between metals and alpha-synuclein--function or artefact?
    Brown DR
    FEBS J; 2007 Aug; 274(15):3766-74. PubMed ID: 17617226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-synuclein dysfunction in Lewy body diseases.
    Tofaris GK; Spillantini MG
    Mov Disord; 2005 Aug; 20 Suppl 12():S37-44. PubMed ID: 16092089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
    Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
    Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards multiparametric fluorescent imaging of amyloid formation: studies of a YFP model of alpha-synuclein aggregation.
    van Ham TJ; Esposito A; Kumita JR; Hsu ST; Kaminski Schierle GS; Kaminski CF; Dobson CM; Nollen EA; Bertoncini CW
    J Mol Biol; 2010 Jan; 395(3):627-42. PubMed ID: 19891973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR.
    Ramakrishnan M; Jensen PH; Marsh D
    Biochemistry; 2006 Mar; 45(10):3386-95. PubMed ID: 16519533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of alpha-synuclein in neurodegenerative diseases.
    Bennett MC
    Pharmacol Ther; 2005 Mar; 105(3):311-31. PubMed ID: 15737408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural characterization of the intrinsically unfolded protein beta-synuclein, a natural negative regulator of alpha-synuclein aggregation.
    Bertoncini CW; Rasia RM; Lamberto GR; Binolfi A; Zweckstetter M; Griesinger C; Fernandez CO
    J Mol Biol; 2007 Sep; 372(3):708-22. PubMed ID: 17681539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity.
    Wang X; Moualla D; Wright JA; Brown DR
    J Neurochem; 2010 May; 113(3):704-14. PubMed ID: 20141569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidation and nitration of α-synuclein and their implications in neurodegenerative diseases.
    Chavarría C; Souza JM
    Arch Biochem Biophys; 2013 May; 533(1-2):25-32. PubMed ID: 23454347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship between alpha-synuclein and Parkinson's disease].
    Nishioka K; Hattori N
    Brain Nerve; 2007 Aug; 59(8):825-30. PubMed ID: 17713118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.
    Klucken J; Ingelsson M; Shin Y; Irizarry MC; Hedley-Whyte ET; Frosch M; Growdon J; McLean P; Hyman BT
    Acta Neuropathol; 2006 Feb; 111(2):101-8. PubMed ID: 16482476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein, Abeta and Alzheimer's disease.
    Wirths O; Bayer TA
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):103-8. PubMed ID: 12551731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers.
    Näsström T; Wahlberg T; Karlsson M; Nikolajeff F; Lannfelt L; Ingelsson M; Bergström J
    Biochem Biophys Res Commun; 2009 Jan; 378(4):872-6. PubMed ID: 19070597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic mutations shift the equilibria of alpha-synuclein single molecules towards structured conformers.
    Brucale M; Sandal M; Di Maio S; Rampioni A; Tessari I; Tosatto L; Bisaglia M; Bubacco L; Samorì B
    Chembiochem; 2009 Jan; 10(1):176-83. PubMed ID: 19067456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
    Meredith SC
    Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the aggregation of an amyloidogenic alpha-synuclein peptide fragment.
    Madine J; Doig AJ; Kitmitto A; Middleton DA
    Biochem Soc Trans; 2005 Nov; 33(Pt 5):1113-5. PubMed ID: 16246058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.